Ronny I Drapkin

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas
    Ronny Drapkin
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:2162-9. 2005
  2. ncbi Urokinase-type plasminogen activator receptor: a beacon of malignancy?
    Ronny Drapkin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 14:5643-5. 2008
  3. ncbi PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma
    Anna R Laury
    Department of Pathology Section, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Surg Pathol 34:627-35. 2010
  4. ncbi Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival
    Adam Clauss
    Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02115, USA
    Neoplasia 12:161-72. 2010
  5. ncbi Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia
    Ronny Drapkin
    Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
    Hum Pathol 35:1014-21. 2004
  6. ncbi New insights into the pathogenesis of serous ovarian cancer and its clinical impact
    Keren Levanon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5284-93. 2008
  7. ncbi Serous carcinogenesis in the fallopian tube: a descriptive classification
    Elke Jarboe
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 27:1-9. 2008
  8. ncbi An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells
    Qing Sheng
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 17:298-310. 2010
  9. ncbi A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function
    Arcangela De Nicolo
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 14:4672-80. 2008
  10. ncbi Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma
    Veerle Bossuyt
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 27:390-7. 2008

Research Grants

  1. BACH1 Function in DNA Repair and Mammary Oncogenesis
    Ronny Drapkin; Fiscal Year: 2007

Collaborators

  • Marisa R Nucci
  • J L Hecht
  • Christopher P Crum
  • Elke Jarboe
  • U A Matulonis
  • S C Mok
  • M Meyerson
  • Joyce F Liu
  • Qing Sheng
  • Huiying Piao
  • Anna R Laury
  • Adam Clauss
  • Michelle S Hirsch
  • Vivian Ng
  • David M Livingston
  • Veerle Bossuyt
  • Keren Levanon
  • Arcangela De Nicolo
  • Koji Nozaki
  • Daniel P Silver
  • Regina Groisman
  • Tomas Bonome
  • Jeffrey F Krane
  • Michael J Birrer
  • Heidi Greulich
  • Joseph Corson
  • Zeinab Moustafa
  • Azra H Ligon
  • Seth Ettenberg
  • Roman K Thomas
  • Natalie Vena
  • Jinyun Chen
  • David Batt
  • Xinggang Liu
  • Sara Zaghlul
  • William C Hahn
  • Moises Russo
  • Andrew L Kung
  • Jason L Hornick
  • Ruth Perets
  • Karen Yuan
  • Anna Schinzel
  • Birgit Schoeberl
  • Eleanor Fleming
  • Cristina Chantal Flemma
  • Ann K Folkins
  • Claudio Di Cristofano
  • Masako Ogawa
  • Generoso Bevilacqua
  • James R Goldenring
  • Fabiola Medeiros
  • Stephen F Konieczny
  • Mariella Tancredi
  • Serena Barbuti
  • Maria Adelaide Caligo
  • Jason C Mills
  • Bonnie J Lafleur
  • Sachiyo Nomura
  • Bijan Sobhian
  • Grazia Lombardi
  • Janice A Williams
  • Sven Rottenberg
  • Nicholas Denunzio
  • Rebecca Gelman
  • Shihua D Lu
  • Jean Feunteun
  • Stoil D Dimitrov
  • Elena Shestakova
  • Shridar Ganesan
  • Xiaoling Liu
  • Serban Dragomir
  • Soundarapandian Velmurugan
  • Jessica Mar
  • Jos Jonkers
  • Yoshihiro Nakatani
  • Jolanta Polanowska
  • Kiyoji Tanaka
  • Jun-ichi Sawada
  • Alexei F Kisselev
  • Masafumi Saijo
  • Jun Ichi Sawada
  • Isao Kuraoka

Detail Information

Publications16

  1. ncbi Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas
    Ronny Drapkin
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:2162-9. 2005
    ..Its expression in cortical inclusion cysts suggests that formation of Mullerian epithelium is a prerequisite step in the development of some types of EOCs...
  2. ncbi Urokinase-type plasminogen activator receptor: a beacon of malignancy?
    Ronny Drapkin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 14:5643-5. 2008
    ..Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies...
  3. ncbi PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma
    Anna R Laury
    Department of Pathology Section, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Surg Pathol 34:627-35. 2010
    ..The presence of weak staining for PAX8 in the 3 "noninvasive" mesotheliomas questions the use for PAX8 in this differential diagnosis. On the basis of this study, h-caldesmon is not a useful marker for mesothelioma...
  4. ncbi Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival
    Adam Clauss
    Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02115, USA
    Neoplasia 12:161-72. 2010
    ..These results, combined with our observation that Elafin is secreted by ovarian tumors and is minimally expressed in normal tissues, suggest that Elafin may serve as a determinant of poor survival in this disease...
  5. ncbi Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia
    Ronny Drapkin
    Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
    Hum Pathol 35:1014-21. 2004
    ..This immunophenotype is preserved in ovarian carcinomas, suggesting that Müllerian metaplasia signals the acquisition of these markers and that their expression is maintained in ovarian carcinomas that originate from this epithelium...
  6. ncbi New insights into the pathogenesis of serous ovarian cancer and its clinical impact
    Keren Levanon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5284-93. 2008
    ..With the rise of the fallopian tube secretory epithelial cell as a cell of origin for high-grade pelvic serous carcinomas, the need to develop tools and model systems to characterize the biology and physiology of this cell is recognized...
  7. ncbi Serous carcinogenesis in the fallopian tube: a descriptive classification
    Elke Jarboe
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 27:1-9. 2008
    ..Combined with recent reports associating STICs with pelvic serous cancer, this continuum of epithelial change validates the SCAT sequence and the fimbrial secretory cell as the site of origin for many serous carcinomas...
  8. ncbi An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells
    Qing Sheng
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 17:298-310. 2010
    ..Furthermore, a monoclonal ErbB3-directed antibody (MM-121) also significantly inhibited tumor growth in vivo. These findings identify ErbB3 as a potential therapeutic target in ovarian cancer...
  9. ncbi A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function
    Arcangela De Nicolo
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 14:4672-80. 2008
    ..We aimed to assess whether BRIP1 mutations contribute to breast cancer susceptibility in our population and, if so, to investigate the effect of such mutation(s) on BRIP1 function...
  10. ncbi Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma
    Veerle Bossuyt
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 27:390-7. 2008
    ..Whether the shared tumor phenotype in these 2 organs is coincidental or interdependent bears further investigation...
  11. ncbi The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage
    Regina Groisman
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cell 113:357-67. 2003
    ..Knockdown of CSN with RNA interference leads to defects in NER. These results suggest that the distinct UV response of the DDB2 and CSA complexes is involved in diverse mechanisms of NER...
  12. ncbi Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications
    Marisa R Nucci
    Department of Pathology, Divisions of Women s and Perinatal Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am J Surg Pathol 31:737-43. 2007
    ....
  13. ncbi Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer
    Christopher P Crum
    Department of Pathology, Brigham and Womens Hospital, 75 Francis Street, Boston, MA 02115, USA
    Clin Med Res 5:35-44. 2007
    ....
  14. ncbi Further evidence for BRCA1 communication with the inactive X chromosome
    Daniel P Silver
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cell 128:991-1002. 2007
    ..Here we discuss recently published data from our laboratory and others and present new results that, together, provide further support for a role of BRCA1 in the regulation of XIST concentration on Xi in somatic cells...
  15. ncbi The distal fallopian tube: a new model for pelvic serous carcinogenesis
    Christopher P Crum
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Curr Opin Obstet Gynecol 19:3-9. 2007
    ....
  16. ncbi A molecular signature of gastric metaplasia arising in response to acute parietal cell loss
    Koji Nozaki
    Nashville VA Medical Center and the Department of Surgery, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Gastroenterology 134:511-22. 2008
    ..We now sought to characterize more definitively the pathway for emergence of SPEM...

Research Grants2

  1. BACH1 Function in DNA Repair and Mammary Oncogenesis
    Ronny Drapkin; Fiscal Year: 2007
    ..The sponsor, Dr. David Livingston, is a recognized world-leader in cancer biology with a strong record of training successful basic investigators. ..